Most Active Stocks: Synovus Financial Corp. (NYSE:SNV), Exact Sciences Corporation (NASDAQ:EXAS)

Synovus Financial Corp. (NYSE:SNV)

Morgan Stanley Upgrades Synovus Financial Corp. (NYSE:SNV)’s stock to Overweight with the price target of $50. This rating was issued on 11/12/18. The stock recently closed its previous session at $37.7 by showing a percentage change of 0.4% from its previous day closing price of $37.55.

Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on Synovus Financial Corp. (NYSE:SNV) in which Keefe Bruyette & Woods Upgrades Synovus Financial Corp. (NYSE:SNV) to Outperform by settling a price target of $55 on 11/09/18. Barclays Maintains the stock to Equal-Weight on 10/24/18 by stationing a price target of $47. Barclays Maintains the company’s stock to Equal-Weight on 10/03/18 by setting a price target of $55. Morgan Stanley Maintains Synovus Financial Corp. (NYSE:SNV) to Equal-Weight with a price target of $55.

Synovus Financial Corp. (NYSE:SNV) currently has a consensus Price Target of $49.34. While some analysts have a High Price target for the stock of $56.5 and a Low Price Target of $42.

Several sell side analysts reviewed their recommendations on Synovus Financial Corp. (NYSE:SNV) where 1 analyst have rated the stock as Strong Buy, 6 analysts said it’s a Buy, 10 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 2.32. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, Synovus Financial Corp. (NYSE:SNV) reported its Actual EPS of $0.84/share. The analysts offering Earnings Estimates for the company were believing that Synovus Financial Corp. (NYSE:SNV) could bring EPS of $0.92/share. The difference between Actual EPS and Estimated EPS was -0.08 Percent. Thus the company showed an Earnings Surprise of -8.7 Percent.

Synovus Financial Corp. (NYSE:SNV) has a market capitalization of 4.39 Billion. The stock traded with the volume of 1.57 Million shares in the last trading session. The stock touched its high share price of $57.40 on 06/11/18 and the stock also touched its Lowest price in the last 52-weeks of trading on 10/26/18 as $36.24. The company has a 1 Year high price target of $50.26. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of -2.82%. The Moving Average SMA50 is -13.6% while SMA200 is -24.32%.

Synovus Financial Corp. (NYSE:SNV) is currently showing its ROA (Return on Assets) of 1.1%. The Return on Investment (ROI) is at 23.5% while it’s Return on Equity (ROE) value stands at 11.8%. The stock currently shows its YTD (Year to Date) performance of -21.36 percent while its Weekly performance value is -1.21%. The Monthly and Yearly performances are -12.26 percent and -17.42 percent respectively. The Relative Volume value measured for Synovus Financial Corp. (NYSE:SNV) is 0.96. The Average Volume (3 months) is 1.63 Million.

The stock currently has its Annual Dividend of $1 and an annual Dividend Yield of 2.65 Percent. SNV has P/E (Price to Earnings ttm) value of 11.75, Forward P/E of 9.36, P/C (Price to cash per share) of 4.37 and Price to Free Cash Flow (P/FCF) value of 10.7. The stock is showing its Operating Margin of 82.8 percent.

Company Profile:

Synovus Financial Corp. is a financial services company and a registered bank holding company headquartered in Columbus, Georgia. The Company provides integrated financial services including commercial and retail banking, financial management, insurance and mortgage services to its customers through banking divisions of its wholly-owned subsidiary bank, Synovus Bank, and other offices in Georgia, Alabama, South Carolina, Florida and Tennessee. The Company’s relationship-driven community banking model is built on creating long-term relationships with our customers. This relationship banking approach allows its bankers to serve their customers’ individual needs and demonstrates its commitment to the communities in which it operate.

Exact Sciences Corporation (NASDAQ:EXAS)

Jefferies Maintains Exact Sciences Corporation (NASDAQ:EXAS)’s stock to Buy with the price target of $84. This rating was issued on 10/31/18. The stock recently closed its previous session at $69.41 by showing a percentage change of 1.7% from its previous day closing price of $68.25.

Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on Exact Sciences Corporation (NASDAQ:EXAS) in which Canaccord Genuity Maintains Exact Sciences Corporation (NASDAQ:EXAS) to Buy by settling a price target of $87 on 9/12/18. Baird Maintains the stock to Outperform on 9/11/18 by stationing a price target of $85. Bank of America Maintains the company’s stock to Buy on 9/06/18 by setting a price target of $92. Baird Maintains Exact Sciences Corporation (NASDAQ:EXAS) to Outperform with a price target of $74.

Exact Sciences Corporation (NASDAQ:EXAS) currently has a consensus Price Target of $88. While some analysts have a High Price target for the stock of $100 and a Low Price Target of $75.

Several sell side analysts reviewed their recommendations on Exact Sciences Corporation (NASDAQ:EXAS) where 8 analyst have rated the stock as Strong Buy, 2 analysts said it’s a Buy, 3 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 1.36. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, Exact Sciences Corporation (NASDAQ:EXAS) reported its Actual EPS of $-0.37/share. The analysts offering Earnings Estimates for the company were believing that Exact Sciences Corporation (NASDAQ:EXAS) could bring EPS of $-0.43/share. The difference between Actual EPS and Estimated EPS was 0.06 Percent. Thus the company showed an Earnings Surprise of 14 Percent.

Exact Sciences Corporation (NASDAQ:EXAS) has a market capitalization of 8.53 Billion. The stock traded with the volume of 1.56 Million shares in the last trading session. The stock touched its high share price of $81.22 on 09/25/18 and the stock also touched its Lowest price in the last 52-weeks of trading on 04/06/18 as $37.36. The company has a 1 Year high price target of $88. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of 2.07%. The Moving Average SMA50 is -3.44% while SMA200 is 18.79%.

Exact Sciences Corporation (NASDAQ:EXAS) is currently showing its ROA (Return on Assets) of -11.8%. The Return on Investment (ROI) is at -46.3% while it’s Return on Equity (ROE) value stands at -21.4%. The stock currently shows its YTD (Year to Date) performance of 32.11 percent while its Weekly performance value is -6.48%. The Monthly and Yearly performances are 5.53 percent and 19.22 percent respectively. The Relative Volume value measured for Exact Sciences Corporation (NASDAQ:EXAS) is 0.74. The Average Volume (3 months) is 2.12 Million.

The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. EXAS has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 7.34 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of -33.4 percent.

Company Profile:

EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.